scispace - formally typeset
D

David J. Johnson

Researcher at University of Guelph

Publications -  15
Citations -  2387

David J. Johnson is an academic researcher from University of Guelph. The author has contributed to research in topics: Lemna gibba & Toxicity. The author has an hindex of 14, co-authored 15 publications receiving 2156 citations. Previous affiliations of David J. Johnson include Canadian Food Inspection Agency.

Papers
More filters
Journal ArticleDOI

Ranking and prioritization of environmental risks of pharmaceuticals in surface waters.

TL;DR: Cardiovascular, gastrointestinal, antiviral, anxiolytic sedatives hypnotics and antipsychotics, corticosteroid, and thyroid pharmaceuticals were the predicted most hazardous therapeutic classes.
Journal ArticleDOI

Probabilistic hazard assessment of environmentally occurring pharmaceuticals toxicity to fish, daphnids and algae by ECOSAR screening.

TL;DR: (Q)SAR's can be important prioritization tools for subsequent experimental risk assessment of pharmaceuticals in surface waters, due to the prevalent lack of ecotoxicological data.
Journal ArticleDOI

Effects of 25 pharmaceutical compounds to Lemna gibba using a seven-day static-renewal test.

TL;DR: Injury symptoms were comparatively uniform and consistent among chemical classes while degree of phytotoxicity varied considerably; both of these criteria varied markedly between classes.
Journal ArticleDOI

Aquatic persistence of eight pharmaceuticals in a microcosm study

TL;DR: No significant differences were observed between measured half‐lives of the pharmaceuticals in sunlight‐exposed pond water and autoclaved pond water, which suggests photode degradation was important in limiting their persistence, and biodegradation was not an important loss process in surface water over the duration of the study.
Journal ArticleDOI

Toxicity classification and evaluation of four pharmaceuticals classes: antibiotics, antineoplastics, cardiovascular, and sex hormones

TL;DR: Q)SARs and pharmacodynamic information should be used to prioritize and steer experimental risk assessments of pharmaceuticals, and potentially, also be used in new drug discovery optimizing efficacy and in minimising environmental hazards of new products.